Korea Otsuka Pharmaceutical Co., Ltd.
🇰🇷South Korea
Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
Not yet recruiting
- Conditions
- Tuberculosis, Multidrug-Resistant
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT06674291
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
Recruiting
- Conditions
- Chronic GastritisAcute Gastritis
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05048069
- Locations
- 🇰🇷
Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
Phase 3
Completed
- Conditions
- Acute GastritisChronic Gastritis
- Interventions
- Drug: MCT-SR
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT04189705
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04150172
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Korea, Republic of
To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04150146
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Bundang, Gyeonggi-do, Korea, Republic of
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
Phase 4
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT03949894
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of
Iclusig PMS in CML or Ph+ALL Patients
Active, not recruiting
- Conditions
- Chronic Myeloid LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03709017
- Locations
- 🇰🇷
Kosin University Gaspel Hospital, Busan, Korea, Republic of
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Completed
- Conditions
- Multi-drug Resistant Tuberculosis
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT03470233
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Phase 3
Recruiting
- Conditions
- Depression, Bipolar
- Interventions
- Drug: Placebo of Abilify 2, 5, 10, 15mg (Tablet)
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT03423680
- Locations
- 🇰🇷
Seounl National University Hospital, Seoul, Korea, Republic of
Samsca PMS in ADPKD Patients
Recruiting
- Conditions
- Safety
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT03406286
- Locations
- 🇰🇷
Kim Med Clinic, Ulsan, Gyeongsangnam-do, Korea, Republic of